Chemical Namebrexpiprazole
Dosage FormTablet (oral; 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg)
Drug ClassAtypical antipsychotics
CompanyOtsuka Pharmaceutical
Approval Year2015


  • Indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
  • Indicated for the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
Document TitleYearSource
Rexulti (brexpiprazole) Prescribing Information.2021Otsuka America Pharmaceutical, Inc., Rockville, MD
Document TitleYearSource
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis.2022Psychiatry and Clinical Neurosciences
Efficacy and safety of adjunctive serotonin-dopamine activity modulators in major depression: a meta-analysis of randomized controlled trials. 2022Journal of Clinical Pharmacology
Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis.2022Journal of Affective Disorders
Efficacy and safety of antipsychotic treatments for schizophrenia: a systematic review and network meta-analysis of randomized trials in Japan.2021Journal of Psychiatric Research
Blonanserin patch vs. other antipsychotics for acute schizophrenia: a systematic review of double-blind, randomized, placebo-controlled, phase 3 trials in Japan.2020Pharmacopsychiatry
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.2020Psychopharmacology
Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis.2019International Journal of Neuropsychopharmacology
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.2019Lancet
Australian public assessment report for brexpiprazole.2018Australian Government: Department of Health
Assessment report: Rexulti.2018EMA
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials.2018Neuropsychiatric Disease and Treatment
Drug updated on 6/1/2023

More on this drug: Clinical Trials